Form 4: Coeptis Therapeutics Holdings Executive Buys Shares
Insider Transaction (Form 4)
Christopher Ryan Schadel, Chief Marketing Officer of Coeptis Therapeutics Holdings, Inc., purchased 1,000 shares of common stock on August 18, 2026 for $3.92 per share.
Summary
- Open-market purchase: acquired 1,000 Common Stock at $3.92 ($3,920) on August 18, 2026; holds 1,000 after (Direct).
- Grant/award: acquired 2,806 Restricted Stock Units on June 3, 2026; holds 12,674 after (Direct).
- Grant/award: acquired 100,000 Stock Option (Right to Buy) on April 27, 2026; holds 100,000 after (Direct).
- Grant/award: acquired 9,868 Restricted Stock Units on April 27, 2026; holds 9,868 after (Direct).
Sentiment
Score: 7
Explanation: StockSavvy.ai views this as a bullish signal: an insider made an open-market purchase of $3,920, committing personal capital to the stock.
Insider Transactions
Christopher Ryan Schadel — Officer (Chief Marketing Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-18 | Open-market purchase | Common Stock | 1,000 | $4 | $3.9K | 1,000 |
| 2026-06-03 | Grant/award | Restricted Stock Units | 2,806 | — | — | 12,674 |
| 2026-04-27 | Grant/award | Stock Option (Right to Buy) | 100,000 | — | — | 100,000 |
| 2026-04-27 | Grant/award | Restricted Stock Units | 9,868 | — | — | 9,868 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-18 | Open-market purchase (1,000 shares) |
| 2026-06-03 | Grant/award (2,806 shares) |
| 2026-04-27 | Grant/award (100,000 shares) |
| 2026-04-27 | Grant/award (9,868 shares) |
Keywords
insider transaction, Form 4, ZSQR, Z Squared Inc., bullish, Christopher Ryan Schadel
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.